Journal of Clinical Oncology最新文献

{"title":"Looking for the Best Allogeneic Donor and the BMT CTN 1702 Study: Noli Tempus Perdere.","authors":"Alessandro Rambaldi","doi":"10.1200/jco-25-01884","DOIUrl":"https://doi.org/10.1200/jco-25-01884","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"28 1","pages":"JCO2501884"},"PeriodicalIF":45.3,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145194759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis.","authors":"Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen, Sara Lonardi, David Tougeron, Gianmarco Ricagno, Floriana Nappo, Ferdinando De Vita, Matthew Nankivell, David Cunningham, Jeeyun Lee, Won Ki Kang, Jae-Ho Cheong, Yoon Young Choi, Giovanni Randon, Michele Prisciandaro, Chiara C Pircher, Paolo Manca, Margherita Ambrosini, Roberta Fazio, Francesca Bergamo, Guillaume Piessen, Elizabeth C Smyth, Dominik Paul Modest, Rosalba Miceli, Thierry André, Filippo Pietrantonio","doi":"10.1200/JCO-25-00447","DOIUrl":"https://doi.org/10.1200/JCO-25-00447","url":null,"abstract":"<p><strong>Purpose: </strong>Patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA) have better survival after surgery and scant/no benefit from chemotherapy. Preoperative immune checkpoint inhibitors (ICIs) demonstrated a high proportion of major complete pathologic response, possibly allowing chemotherapy/surgery-free approaches.</p><p><strong>Methods: </strong>Individual patient data pooled analysis was performed to determine an optimal strategy for resectable dMMR/MSI-H GEA. Patients were stratified across four groups: neoadjuvant dual CTLA-4/PD-(L)1 ICIs with or without surgery, perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) and surgery, and surgery alone or with older perioperative/adjuvant chemotherapy regimens. Primary end points were pathologic complete and major complete pathologic response proportion (pathologic complete response [pCR], tumor regression grade [TRG]1a, major pathologic response [MPR], TRG1a/b Becker criteria) in resected patients. Secondary end points were event-free survival (EFS) and overall survival (OS) in the overall population.</p><p><strong>Results: </strong>Among 197 patients, 49 received ICIs, 27 FLOT, 33 surgery alone, and 88 older chemotherapy regimens. Among 69 patients who underwent surgery after ICIs or FLOT, ICIs demonstrated significantly higher pathologic response versus FLOT (pCR, 61.9% <i>v</i> 3.7%; odds ratio [OR], 54.8; <i>P</i> = .002; MPR, 78.6% <i>v</i> 10%; OR, 39.3; <i>P</i> < .001) and lower ypN+ (14.3% <i>v</i> 37%; OR, 4.2; <i>P</i> = .015) and ypT (OR, 16.4; <i>P</i> < .001) stage. No significant differences in EFS/OS were observed (the 36-month EFS and OS were 70.4% <i>v</i> 80.6% and 72.7% <i>v</i> 90.4% with ICI <i>v</i> surgery alone). Residual nodal disease (ypN+) or ypT4 status after neoadjuvant ICIs or FLOT and nonpathologic response status were associated with inferior progression-free survival/OS.</p><p><strong>Conclusion: </strong>In resectable dMMR/MSI-H GEA, neoadjuvant ICIs significantly increase pathologic response and downstaging versus FLOT, with comparable EFS/OS with surgery with or without chemotherapy. The higher proportion of ypN0 and lack of ypT4 after neoadjuvant ICIs versus FLOT should drive preoperative treatment choices in clinical high-risk disease. The high proportion of pCR/MPR with ICIs provides rationale for exploring organ-sparing surgery or nonoperative management.</p>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2500447"},"PeriodicalIF":41.9,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145191707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial.","authors":"Andrea Gallamini, Corrado Tarella, Simonetta Viviani, Andrea Rossi, Caterina Patti, Antonino Mulé, Marco Picardi, Alessandra Romano, Maria Cantonetti, Giorgio La Nasa, Livio Trentin, Silvia Bolis, Davide Rapezzi, Roberta Battistini, Daniela Gottardi, Paolo Gavarotti, Paolo Corradini, Michele Cimminiello, Corrado Schiavotto, Guido Parvis, Roberta Zanotti, Guido Gini, Andrés J M Ferreri, Piera Viero, Maurizio Miglino, Atto Billio, Abraham Avigdor, Alberto Biggi, Federico Fallanca, Umberto Ficola, Michele Gregianin, Agostino Chiaravalloti, Giuseppe Prosperini, Fabrizio Bergesio, Stephane Chauvie, Chiara Pavoni, Alessandro Massimo Gianni, Alessandro Rambaldi","doi":"10.1200/JCO-25-02137","DOIUrl":"https://doi.org/10.1200/JCO-25-02137","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502137"},"PeriodicalIF":41.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality.","authors":"Maureen E Canavan,Lee Cheng,Jenny Jing Xiang,John Kent Lin,David Hui,Hui Zhao,Nico Nortje,Ravin Ratan,Nathan Cherny,Trinh Pham,Sharon H Giordano,Jiangong Niu,Kerin B Adelson","doi":"10.1200/jco-25-00530","DOIUrl":"https://doi.org/10.1200/jco-25-00530","url":null,"abstract":"PURPOSEUse of cytotoxic chemotherapy at end-of-life (EOL) is associated with adverse quality of life, increased health care utilization, and lower hospice rates. Although EOL cytotoxic chemotherapy use has declined in recent years, EOL novel (immunotherapy and targeted therapy) use has increased. The association between use of novel therapies at EOL and health care utilization has not been widely studied.METHODSWe identified patients within SEER-Medicare who had part D coverage (excluding those with Medicare Advantage) age 66 years and older, and breast, colorectal, lung, prostate, bladder, cervical, kidney, liver, ovarian, pancreatic, melanoma, or uterine cancer. Patients were diagnosed between 2005 and 2019 and died between 2015 and 2020. We analyzed associations between EOL systemic anticancer therapy (SACT) use (overall and by subtype), and health care utilization in the last 30 days of life (emergency department [ED], hospitalization, intensive care unit [ICU], and inpatient death), and hospice with multivariable regression, controlling for sociodemographic and cancer covariates.RESULTSOf 315,089 beneficiaries, 23,970 (7.6%) received SACT within 30 days of death. The breakdown by type was cytotoxic therapy 50.6%, immunotherapy 20.8%, targeted therapy 18%, and combination therapies 10.6%. After adjusting for covariates, any SACT use at EOL was associated with higher ED use (odds ratio [OR], 3.05 [95% CI, 2.95 to 3.15]), hospital admissions (OR, 2.64 [95% CI, 2.56 to 2.72]), ICU admission (OR, 1.78 [95% CI, 1.72 to 1.83]), hospital death (OR, 2.02 [95% CI, 1.96 to 2.08]), and lower hospice use (OR, 0.51 [95% CI, 0.50 to 0.53]) compared with no SACT. All subtypes of SACT were individually associated with higher health care utilization and lower hospice use (P < .001).CONCLUSIONAll subtypes of SACT use were associated with markers of worse-quality EOL care. These data can inform decisions for current care guidelines and efforts to reduce overutilization.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"17 1","pages":"JCO2500530"},"PeriodicalIF":45.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: Phase II Study of ¹⁷⁷Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.","authors":"Frank I Lin, Jaydira Del Rivero, Jorge A Carrasquillo, Abhishek Jha, Joy Zou, Inna Shamis, Sara Talvacchio, Baris Turkbey, Erich P Huang, Joanna Shih, Joanna Klubo-Gwiezdzinska, Esther Mena, Liza Lindenberg, Yating Teng, Freddy E Escorcia, Clara Chen, Peter Herscovitch, Corina Millo, Peter L Choyke, Karel Pacak","doi":"10.1200/JCO-25-02180","DOIUrl":"https://doi.org/10.1200/JCO-25-02180","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502180"},"PeriodicalIF":41.9,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145175595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era.","authors":"Tafadzwa L Chaunzwa,Salma K Jabbour,Luke R G Pike,Alissa J Cooper,Narek Shaverdian,Daniel Gomez","doi":"10.1200/jco-25-01817","DOIUrl":"https://doi.org/10.1200/jco-25-01817","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"4 1","pages":"JCO2501817"},"PeriodicalIF":45.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145153353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.","authors":"Eunice S Wang,Pau Montesinos,James Foran,Harry Erba,Eduardo Rodríguez-Arbolí,Kateryna Fedorov,Maël Heiblig,Florian H Heidel,Jessica K Altman,Maria R Baer,Lionel Ades,Kristen Pettit,Pierre Peterlin,Cristina Papayannidis,Céline Berthon,Roland B Walter,Mithun V Shah,Suresh Balasubramanian,Mohamad Khawandanah,Olga Salamero Garcia,Julie Bergeron,Yazan F Madanat,Gail J Roboz,Matthew Ulrickson,Robert L Redner,James McCloskey,Arnaud Pigneux,Adolfo de la Fuente Burguera,Amitava Mitra,Harris S Soifer,Marilyn Tabachri,Zijing Zhang,Marcie Riches,Daniel Corum,Mollie Leoni,Ghayas C Issa,Amir T Fathi, ","doi":"10.1200/jco-25-01694","DOIUrl":"https://doi.org/10.1200/jco-25-01694","url":null,"abstract":"PURPOSEZiftomenib-a potent, highly selective, oral menin inhibitor-was well tolerated and demonstrated encouraging clinical activity as monotherapy for relapsed/refractory NPM1-mutated (NPM1-m) and KMT2A-rearranged AML in the KOMET-001 phase I trial.METHODSIn the registration-enabling phase II part of KOMET-001, patients with relapsed/refractory NPM1-m AML received ziftomenib 600 mg once daily. The primary end point was the rate of complete remission with full hematologic recovery (CR)/CR with partial hematologic recovery (CRh).RESULTSFrom January 26, 2023, to May 13, 2024, 92 patients (median age, 69 years [range, 33-84]) were treated. The primary end point was met, with a CR/CRh rate of 22% (95% CI, 14 to 32; P = .0058); 61% were negative for measurable residual disease. Overall response rate was 33% (95% CI, 23 to 43), with a median duration of 4.6 months (95% CI, 2.8 to 7.4). Prespecified subgroup analyses showed comparable CR/CRh regardless of previous therapy, including venetoclax, or type of comutations. Median overall survival was 6.6 months (95% CI, 3.6 to 8.6). Common grade ≥3 treatment-emergent adverse events were febrile neutropenia (26%), anemia (20%), and thrombocytopenia (20%). Differentiation syndrome occurred in 25% of patients (15% grade 3; no grade 4-5) and was manageable with protocol-defined mitigation. Three patients (3%) discontinued treatment because of ziftomenib-related adverse events.CONCLUSIONZiftomenib demonstrated significant clinical benefit and deep responses in patients with heavily pretreated, relapsed/refractory NPM1-m AML. Ziftomenib was well tolerated with a safety profile consistent with previous studies, including manageable differentiation syndrome, lack of clinically significant QTc prolongation, and low rates of myelosuppression.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"64 1","pages":"JCO2501694"},"PeriodicalIF":45.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fusing Oncolytic Virotherapy With Cancer Immunotherapy to Treat Therapy-Resistant Melanoma.","authors":"Richard G Vile","doi":"10.1200/jco-25-01890","DOIUrl":"https://doi.org/10.1200/jco-25-01890","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"95 1","pages":"JCO2501890"},"PeriodicalIF":45.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on Human Epidermal Growth Factor Receptor 2-Low Metastatic Breast Cancer Treatment Costs and Cost-Effectiveness.","authors":"Jiang Wu,Dongxu Ma,Zeyu Xing","doi":"10.1200/jco-25-01656","DOIUrl":"https://doi.org/10.1200/jco-25-01656","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"1 1","pages":"JCO2501656"},"PeriodicalIF":45.3,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145134002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Pancreatic Cancer.","authors":"Jennifer J Knox, Grainne O'Kane, Daniel King, Daniel Laheru, Amber N Habowski, Kenneth Yu, Kimberly Perez, Andrew J Aguirre, Zachary Coyne, Harry Harvey, Ronan A McLaughlin, Raymond W Jang, Robert C Grant, Elena C Elimova, Daniel J Renouf, Sandra Fischer, Kai Duan, Stephanie Ramotar, Gun Ho Jang, Amy Zhang, Craig E Devoe, Harshabad Singh, Michael J Pishvaian, Fieke E M Froeling, Muhammad W Saif, Eileen M O'Reilly, Erica S Tsang, Brian M Wolpin, Julie M Wilson, Anna Dodd, Trevor J Pugh, Xiang Y Ye, Steven Gallinger, David A Tuveson, Faiyaz Notta, Elizabeth M Jaffee","doi":"10.1200/JCO-25-02195","DOIUrl":"https://doi.org/10.1200/JCO-25-02195","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":" ","pages":"JCO2502195"},"PeriodicalIF":41.9,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145137512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}